Blog of the MHRA on Transfer of Analytical Methods
Recommendation

Monday, 21 September 2026 14.00 - 16.00 h
Regulatory Landscape: ECHA, USP, Pharmacopoeias and FDA Enforcement
The regulatory authority of the United Kingdom, the MHRA (Medicines and Healthcare products Regulatory Agency), regularly provides information on GMP-relevant topics in a blog on its website.
In August 2021, the topic "transfer of analytical methods" was addressed here and the GMP requirements listed. In this blog edition the tasks of the transferring parties are exemplified and explained.
Frequent Findings
Likewise, a list of frequently occurring deficiencies and sources of error can be found in this post. According to the MHRA, the following points are among the most frequent findings in the subject area "transfer of analytical methods":
- Equipment not qualified for the transferring method
- The transfer protocol is not followed
- The transfer is performed for only one strength of product, although the method is used for additional strengths
- Methods reference documents from the transferring party, which are not available in the receiving laboratory
- The GAP analyses are not complete
- The method transfer was only performed on one batch with one test of each of the different methods (assays/dissolution, etc.)
To get more details please see the MHRA Inspeectorate Blog "transfer of analytical methods".
Related GMP News
03.09.2026USP Article: Supporting the Detection of Asbestos in Pharmaceutical Talc
02.09.2026USP Publishes Comments Received on Chapter <320>
26.08.2026New USP Requirements for Asbestos Testing in Pharmaceutical Talc
19.08.2026FDA Warning Letter: Averaging Data to Override OOS Findings
12.08.2026ECA's Analytical Control Group Publishes Detailed Report on OOS Survey
12.08.2026BP Publishes Key Insights on Limits in Chromatographic Tests


